Press Release
07 March 2022 08:45:00 CET

Lenalidomide Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lenalidomide Newbury in Sweden as the first country in a Scandinavian registration procedure. Approvals in Denmark and Norway are expected to follow upon finalized national reviews.

Lenalidomide is a prescription drug used to treat multiple myeloma and several other haematological malignancies. Lenalidomide is an immunomodulatory treatment and is taken as a capsule, once daily. The originator Revlimid is marketed in Sweden by Celgene – a BMS company and sales is estimated to be 1,4 billion SEK across Scandinavia in 2021 (source: DLMI Nordic Pharma Insights)

> "We are pleased to see our portfolio of oncology products being approved by the Health Authorities. The approval of Lenalidomide Newbury is another regulatory milestone and we expect additional product approvals during the coming years", says Lars Minor - CEO, Newbury Pharmaceuticals.

Lenalidomide Newbury is part of the oncology pipeline with 11 products expected to be registered in the years ahead. Oncology treatment costs are a big part of the total treatment costs for society and the future launch of Lenalidomide will support efficient use of resources and free-up reserves for new innovative products.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
07 March 2022 08:45:00 CET

Attachments

Lenalidomide Newbury approved by the Swedish Health Authorities